1.
Bioorg Med Chem Lett
; 27(4): 1094-1098, 2017 02 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28089699
RESUMO
The synthesis of a novel class of piperazine benzamide (reverse amides) targeting the human ß3-adrenergic receptor for the treatment of overactive bladder (OAB) is described. The SAR studies directed towards maintaining well established ß3 potency and selectivities while improving the overall pharmacokinetic profile in the reverse amide class will be evaluated. The results and consequences associated with functional activity at the norepinephrine transporter (NET) will also be discussed.